Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues

H. Takeuchi, H. Baba, S. Inutsuka, I. Takahashi, H. Kusumoto, Y. Maehara, K. Sugimachi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The chemosensitivity of 43 human sarcoma tissues, including 18 osteosarcomas, 16 leiomyosarcomas and 9 liposarcomas was compared with that of 28 adenocarcinomas of the stomach using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues were exposed for 3 days to each antitumor drug including adriamycin (ADM), 5-fluorouracil (5-FU), mitomycin C (MMC), cisplatin (CDDP), aclacinomycin A (ACR) and carboquone (CQ), then the cell viability was estimated based on the succinate dehydrogenase (SD) activity determined using [3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H tetrazolium bromide] (MTT). SD activity was significantly lower in the osteosarcoma as compared to that in the adenocarcinoma for ADM, MMC, CDDP, ACR and CQ (p < 0.01) and was higher for ADM (p < 0.05) in cases of leiomyosarcoma and for CDDP (p < 0.01) and ACR (p < 0.05) in cases of liposarcoma. The sensitivity rate was higher in osteosarcoma than in adenocarcinoma for ADM, MMC and CDDP. These findings suggest that patients with osteosarcoma will probably show a fairly good response to antitumor drugs and that when liposarcoma or leiomyosarcoma tumors show resistance to antitumor drugs then resection at the time of initial exploration and combined modalities, including radiation and hyperthemia should be considered.

Original languageEnglish
Pages (from-to)169-171
Number of pages3
JournalAnticancer research
Volume14
Issue number1 A
Publication statusPublished - Jan 1 1994

Fingerprint

Osteosarcoma
Sarcoma
Liposarcoma
Doxorubicin
Succinate Dehydrogenase
Leiomyosarcoma
Carbazilquinone
Adenocarcinoma
Mitomycin
Antineoplastic Agents
Aclarubicin
Fluorouracil
Cisplatin
Cell Survival
Stomach
Radiation
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Takeuchi, H., Baba, H., Inutsuka, S., Takahashi, I., Kusumoto, H., Maehara, Y., & Sugimachi, K. (1994). Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. Anticancer research, 14(1 A), 169-171.

Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. / Takeuchi, H.; Baba, H.; Inutsuka, S.; Takahashi, I.; Kusumoto, H.; Maehara, Y.; Sugimachi, K.

In: Anticancer research, Vol. 14, No. 1 A, 01.01.1994, p. 169-171.

Research output: Contribution to journalArticle

Takeuchi, H, Baba, H, Inutsuka, S, Takahashi, I, Kusumoto, H, Maehara, Y & Sugimachi, K 1994, 'Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues', Anticancer research, vol. 14, no. 1 A, pp. 169-171.
Takeuchi H, Baba H, Inutsuka S, Takahashi I, Kusumoto H, Maehara Y et al. Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. Anticancer research. 1994 Jan 1;14(1 A):169-171.
Takeuchi, H. ; Baba, H. ; Inutsuka, S. ; Takahashi, I. ; Kusumoto, H. ; Maehara, Y. ; Sugimachi, K. / Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. In: Anticancer research. 1994 ; Vol. 14, No. 1 A. pp. 169-171.
@article{926d478646c34946a35fa351333fcd93,
title = "Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues",
abstract = "The chemosensitivity of 43 human sarcoma tissues, including 18 osteosarcomas, 16 leiomyosarcomas and 9 liposarcomas was compared with that of 28 adenocarcinomas of the stomach using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues were exposed for 3 days to each antitumor drug including adriamycin (ADM), 5-fluorouracil (5-FU), mitomycin C (MMC), cisplatin (CDDP), aclacinomycin A (ACR) and carboquone (CQ), then the cell viability was estimated based on the succinate dehydrogenase (SD) activity determined using [3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H tetrazolium bromide] (MTT). SD activity was significantly lower in the osteosarcoma as compared to that in the adenocarcinoma for ADM, MMC, CDDP, ACR and CQ (p < 0.01) and was higher for ADM (p < 0.05) in cases of leiomyosarcoma and for CDDP (p < 0.01) and ACR (p < 0.05) in cases of liposarcoma. The sensitivity rate was higher in osteosarcoma than in adenocarcinoma for ADM, MMC and CDDP. These findings suggest that patients with osteosarcoma will probably show a fairly good response to antitumor drugs and that when liposarcoma or leiomyosarcoma tumors show resistance to antitumor drugs then resection at the time of initial exploration and combined modalities, including radiation and hyperthemia should be considered.",
author = "H. Takeuchi and H. Baba and S. Inutsuka and I. Takahashi and H. Kusumoto and Y. Maehara and K. Sugimachi",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "14",
pages = "169--171",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 A",

}

TY - JOUR

T1 - Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues

AU - Takeuchi, H.

AU - Baba, H.

AU - Inutsuka, S.

AU - Takahashi, I.

AU - Kusumoto, H.

AU - Maehara, Y.

AU - Sugimachi, K.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The chemosensitivity of 43 human sarcoma tissues, including 18 osteosarcomas, 16 leiomyosarcomas and 9 liposarcomas was compared with that of 28 adenocarcinomas of the stomach using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues were exposed for 3 days to each antitumor drug including adriamycin (ADM), 5-fluorouracil (5-FU), mitomycin C (MMC), cisplatin (CDDP), aclacinomycin A (ACR) and carboquone (CQ), then the cell viability was estimated based on the succinate dehydrogenase (SD) activity determined using [3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H tetrazolium bromide] (MTT). SD activity was significantly lower in the osteosarcoma as compared to that in the adenocarcinoma for ADM, MMC, CDDP, ACR and CQ (p < 0.01) and was higher for ADM (p < 0.05) in cases of leiomyosarcoma and for CDDP (p < 0.01) and ACR (p < 0.05) in cases of liposarcoma. The sensitivity rate was higher in osteosarcoma than in adenocarcinoma for ADM, MMC and CDDP. These findings suggest that patients with osteosarcoma will probably show a fairly good response to antitumor drugs and that when liposarcoma or leiomyosarcoma tumors show resistance to antitumor drugs then resection at the time of initial exploration and combined modalities, including radiation and hyperthemia should be considered.

AB - The chemosensitivity of 43 human sarcoma tissues, including 18 osteosarcomas, 16 leiomyosarcomas and 9 liposarcomas was compared with that of 28 adenocarcinomas of the stomach using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues were exposed for 3 days to each antitumor drug including adriamycin (ADM), 5-fluorouracil (5-FU), mitomycin C (MMC), cisplatin (CDDP), aclacinomycin A (ACR) and carboquone (CQ), then the cell viability was estimated based on the succinate dehydrogenase (SD) activity determined using [3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H tetrazolium bromide] (MTT). SD activity was significantly lower in the osteosarcoma as compared to that in the adenocarcinoma for ADM, MMC, CDDP, ACR and CQ (p < 0.01) and was higher for ADM (p < 0.05) in cases of leiomyosarcoma and for CDDP (p < 0.01) and ACR (p < 0.05) in cases of liposarcoma. The sensitivity rate was higher in osteosarcoma than in adenocarcinoma for ADM, MMC and CDDP. These findings suggest that patients with osteosarcoma will probably show a fairly good response to antitumor drugs and that when liposarcoma or leiomyosarcoma tumors show resistance to antitumor drugs then resection at the time of initial exploration and combined modalities, including radiation and hyperthemia should be considered.

UR - http://www.scopus.com/inward/record.url?scp=0028179983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028179983&partnerID=8YFLogxK

M3 - Article

C2 - 8166444

AN - SCOPUS:0028179983

VL - 14

SP - 169

EP - 171

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -